Pacira BioSciences, Inc.

NasdaqGS PCRX

Pacira BioSciences, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: 0.73

Pacira BioSciences, Inc. Debt to Equity Ratio is 0.73 for the Trailing 12 Months (TTM) ending September 30, 2024, a -11.16% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Pacira BioSciences, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was 0.82, a -35.94% change year over year.
Pacira BioSciences, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 1.28, a 55.89% change year over year.
Pacira BioSciences, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 0.82, a -15.03% change year over year.
Pacira BioSciences, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was 0.96, a -1.75% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NasdaqGS: PCRX

Pacira BioSciences, Inc.

CEO	Mr. Frank D. Lee
IPO Date	Feb. 3, 2011
Location	United States
Headquarters	5401 West Kennedy Boulevard
Employees	711
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Key trends

Past 5 years